FDA grant Fast Track Designation to a new drug combination for metastatic CRC

Yes, the FDA has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer (CRC). This combination includes alnodesertib (an ATR inhibitor) and low-dose irinotecan. The designation was given due to the promising results observed in patients with metastatic CRC whose tumors lack the ATM DNA-repair protein.

The mechanism behind this drug combo is particularly innovative. Irinotecan works by damaging the DNA of cancer cells, while alnodesertib blocks the cancer cells' ability to repair that damage. Tumors that are ATM-deficient already have compromised DNA repair systems, making this dual approach especially effective. In clinical trials, many patients with ATM-deficient tumors experienced meaningful tumor shrinkage, offering hope to a group of patients who previously had limited treatment options.

The Fast Track Designation is significant because it aims to accelerate the development, review, and availability of therapies that address unmet medical needs, particularly in high-need patient populations. This designation will help expedite the process of bringing this potentially transformative therapy to patients battling metastatic CRC.